We were unable to detect T-cell expansion in our in vivo study using PDXs, which we hypothesize is likely due to lower disease burden at time of treatment, in addition to potential FH FOLR1-CART trafficking to active tumor sites. This evidence concerns the gene CARTPT and neoplasm.